Chapter 2: Pathophysiology of Alzheimer's disease

Shelley Allen-Birt

Research output: Chapter in Book/Report/Conference proceedingChapter in a book

165 Downloads (Pure)

Abstract

•The neuropathological diagnosis of Alzheimer’s disease (AD), requires the presence of amyloid plaques and neurofibrillary tangles, which comprise β-amyloid (Aβ) and tau protein fragments respectively. This diagnosis still relies on post-mortem examination for certainty, although this is changing with improved imaging techniques and biomarkers.

•Familial AD (FAD), a rare form of early onset dementia, may result from mutations in one of three genes, APP, PSEN1, or PSEN2, each of which is directly related to the increased production of longer, more toxic forms of Aβ.

•The ‘amyloid hypothesis’ suggests that Aβ is the principal stimulus for both familial and sporadic AD and that the ensuing disease process results from its overproduction or reduced clearance. This is still considered valid although adverse changes in tau are likely to be required to bring about symptoms of dementia.

•Aβ initiates the pathological process. This pathological process is likely to produce variance in pathological and therefore symptomatic outcome due to the large number of genetic, epigenetic and lifestyle variables in individuals, continuing and amplifying this degenerative process.

•The relatively selective vulnerability of projection neurones of the serotonergic, noradrenergic, cholinergic and cortical glutamatergic systems provide the rationale for current pharmacological treatment.

•The most robust risk, after increased age, for sporadic AD is the presence of the APOE e4 allele coding for the apolipoprotein E4 (APOE) protein polymorphism. APOE is involved in Aβ clearance and neuronal repair, whereas APOE4 contributes to an unfavourable outcome through a number of pathways. This may prove a challenge with respect to therapeutic approaches.

•Symptoms become manifest 15–20 years after the initiation of pathological processes. Even mild cognitive impairment may represent an expression of established disease.
Original languageEnglish
Title of host publicationAlzheimer's Disease
EditorsGunhild Waldemar, Alistair Burns
PublisherOxford University Press
Chapter2
Number of pages10
Edition2nd
ISBN (Print)9780198779803
DOIs
Publication statusPublished - 30 May 2017

Publication series

NameOxford Neurology Library
PublisherOxford University Press

Fingerprint Dive into the research topics of 'Chapter 2: Pathophysiology of Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Allen-Birt, S. (2017). Chapter 2: Pathophysiology of Alzheimer's disease. In G. Waldemar, & A. Burns (Eds.), Alzheimer's Disease (2nd ed.). (Oxford Neurology Library). Oxford University Press. https://doi.org/10.1093/med/9780198779803.001.0001